|

Cancer Clinical Trials in Michigan

915 recruiting studies across 74 cities

All Trials in Michigan

Phase
Trial Phase Location
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPhase 2Adrian
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaPhase 3Adrian
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Adrian
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersPhase 2Adrian
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/AAdrian
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Adrian
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyPhase 3Adrian
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Adrian
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPhase 3Adrian
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaPhase 3Adrian
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—Alma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Alma
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects—Alma
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers—Alma
E-Mindfulness Approaches for Living After Breast CancerPhase 3Alma
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer SurvivorsPhase 3Alma
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Alma
Family Communications After Genetic TestingN/AAlma
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Alma
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPhase 2Alma
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerPhase 3Alma
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment DelaysN/AAlma
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPhase 3Alma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangePhase 2Alma
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With CancerN/AAlma
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPhase 2Alma
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisPhase 2/3Ann Arbor
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsPhase 3Ann Arbor
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Phase 3Ann Arbor
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)Phase 1/2Ann Arbor
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS TrialPhase 2Ann Arbor
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic CancerPhase 1Ann Arbor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsPhase 1/2Ann Arbor
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsPhase 1/2Ann Arbor
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerPhase 2Ann Arbor
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)—Ann Arbor
A Phase 1 Study of BHV-1530 in Advanced Solid TumorsPhase 1Ann Arbor
A Phase 1 Study of IM-1021 in Participants With Advanced CancerPhase 1Ann Arbor
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1Ann Arbor
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsPhase 1/2Ann Arbor
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerPhase 2Ann Arbor
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaPhase 1/2Ann Arbor
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerPhase 1/2Ann Arbor
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsPhase 2Ann Arbor
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)Phase 2Ann Arbor
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal CancerPhase 2Ann Arbor
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaPhase 2Ann Arbor
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple MyelomaPhase 2Ann Arbor
A Registry for People With Lung Cancer—Ann Arbor
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer PatientsN/AAnn Arbor
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid TumorsPhase 1Ann Arbor
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Ann Arbor
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Phase 3Ann Arbor
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3Ann Arbor
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaPhase 2Ann Arbor
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerPhase 1/2Ann Arbor
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerPhase 1/2Ann Arbor
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyPhase 3Ann Arbor
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerPhase 3Ann Arbor
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerPhase 3Ann Arbor
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2Ann Arbor
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)Phase 2Ann Arbor
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)Phase 3Ann Arbor
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Ann Arbor
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTPhase 2Ann Arbor
A Study of DB-1317 in Selected Advanced/Metastatic Solid TumorsPhase 1Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3Ann Arbor
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Phase 1Ann Arbor
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyPhase 3Ann Arbor
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 2Ann Arbor
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)Phase 2Ann Arbor
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsPhase 1Ann Arbor
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )Phase 1Ann Arbor
A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaPhase 2Ann Arbor
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2Ann Arbor
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisPhase 2/3Ann Arbor
A Study of PHST001 in Advanced Solid TumorsPhase 1Ann Arbor
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Phase 3Ann Arbor
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPhase 1/2Ann Arbor
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)Phase 3Ann Arbor
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsPhase 3Ann Arbor
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaPhase 1/2Ann Arbor
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaPhase 2Ann Arbor
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After TreatmentPhase 2Ann Arbor
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPhase 3Ann Arbor
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal CancerPhase 4Ann Arbor
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing LossPhase 3Ann Arbor
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPhase 1/2Ann Arbor
A Study of YL201 in Patients With Advanced Solid TumorsPhase 1/2Ann Arbor
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Phase 1Ann Arbor
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase 3Ann Arbor
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTPhase 2Ann Arbor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaPhase 1Ann Arbor
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-KitPhase 1Ann Arbor
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of DiseasePhase 2Ann Arbor
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)Phase 1/2Ann Arbor
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersPhase 1Ann Arbor
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Ann Arbor
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPhase 3Ann Arbor
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPhase 3Ann Arbor
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerN/AAnn Arbor
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesPhase 2Ann Arbor
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionPhase 2/3Ann Arbor
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaPhase 1Ann Arbor
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaPhase 3Ann Arbor
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsPhase 1Ann Arbor
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaPhase 3Ann Arbor
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesPhase 1Ann Arbor
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Phase 3Ann Arbor
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)Phase 3Ann Arbor
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsPhase 1/2Ann Arbor
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid TumorsPhase 2Ann Arbor
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Phase 3Ann Arbor
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerPhase 2Ann Arbor
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerPhase 3Ann Arbor
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerPhase 3Ann Arbor
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaPhase 2Ann Arbor
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or RectumPhase 2Ann Arbor
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerPhase 2/3Ann Arbor
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsPhase 1Ann Arbor
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaPhase 1Ann Arbor
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyPhase 1Ann Arbor
A Study to Give Treatment Inside the Eye to Treat RetinoblastomaPhase 2Ann Arbor
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)Phase 3Ann Arbor
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLPhase 1Ann Arbor
A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatmentN/AAnn Arbor
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasPhase 2Ann Arbor
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerPhase 2Ann Arbor
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)Phase 1/2Ann Arbor
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaPhase 1/2Ann Arbor
Abatacept in Immune Checkpoint Inhibitor MyocarditisPhase 3Ann Arbor
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.Phase 2Ann Arbor
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPhase 3Ann Arbor
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialPhase 2/3Ann Arbor
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Ann Arbor
An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer SurvivorsN/AAnn Arbor
An Extension Study for Patients Previously Enrolled in Studies With PelabresibPhase 3Ann Arbor
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine CancerEarly 1Ann Arbor
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)—Ann Arbor
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)Phase 2Ann Arbor
Asciminib Roll-over StudyPhase 4Ann Arbor
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerPhase 2Ann Arbor
Avapritinib With Decitabine in Patients With SM-AHNPhase 1Ann Arbor
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaPhase 1Ann Arbor
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPhase 1/2Ann Arbor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Phase 2Ann Arbor
Better Options for Chronic Cancer PainPhase 4Ann Arbor
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyPhase 2Ann Arbor
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCPhase 1/2Ann Arbor
Breast Cancer Resiliency Through Exercise Program (B-REP)N/AAnn Arbor
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in ChildrenPhase 1Ann Arbor
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaPhase 1/2Ann Arbor
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver NodulesN/AAnn Arbor
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast CancerN/AAnn Arbor
COMPASS Study for Metastatic Castration-resistant Prostate Cancer—Ann Arbor
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLPhase 2Ann Arbor
Carboplatin or Olaparib for BRcA Deficient Prostate CancerPhase 2Ann Arbor
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaPhase 3Ann Arbor
Childhood Cancer Survivor Study—Ann Arbor
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Phase 3Ann Arbor
Collection and Storage of Tissue and Blood Samples From Patients With Cancer—Ann Arbor
Collection of Tissue Samples for Cancer Research—Ann Arbor
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePhase 2/3Ann Arbor
Colonoscopy vs Stool Testing for Older Adults With Colon PolypsN/AAnn Arbor
Combination Therapy for the Treatment of Diffuse Midline GliomasPhase 2Ann Arbor
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentPhase 3Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Ann Arbor
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisPhase 3Ann Arbor
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive CisplatinPhase 3Ann Arbor
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaPhase 3Ann Arbor
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity CancerPhase 2/3Ann Arbor
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialPhase 3Ann Arbor
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentPhase 2Ann Arbor
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid CancerPhase 2Ann Arbor
DALY II USA/ MB-CART2019.1 for DLBCLPhase 2Ann Arbor
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyPhase 3Ann Arbor
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerPhase 3Ann Arbor
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Ann Arbor
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPhase 3Ann Arbor
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponsePhase 3Ann Arbor
EDRN Prostate MRI Biomarker Study—Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung CancerPhase 1/2Ann Arbor
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Phase 3Ann Arbor
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerPhase 3Ann Arbor
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)Phase 4Ann Arbor
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies—Ann Arbor
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas—Ann Arbor
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)Phase 1Ann Arbor
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the LungPhase 3Ann Arbor
Excision of Lymph Node Trial (EXCILYNT) (Mel69)N/AAnn Arbor
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy—Ann Arbor
FITting Non-invasive Tests in Lynch Syndrome SurveillanceN/AAnn Arbor
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPhase 2/3Ann Arbor
Fabry Disease Registry & Pregnancy Sub-registry—Ann Arbor
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialPhase 2Ann Arbor
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid TumorsPhase 1Ann Arbor
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPhase 1Ann Arbor
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsN/AAnn Arbor
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyPhase 2Ann Arbor
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerPhase 2Ann Arbor
Gilteritinib for the Treatment of ALK NSCLCPhase 1Ann Arbor
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE TrialPhase 2Ann Arbor
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors—Ann Arbor
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 3Ann Arbor
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerPhase 3Ann Arbor
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaPhase 2Ann Arbor
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 3Ann Arbor
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPhase 3Ann Arbor
International Registry for Men With Advanced Prostate Cancer (IRONMAN)—Ann Arbor
Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe—Ann Arbor
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialPhase 1/2Ann Arbor
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's EsophagusPhase 2Ann Arbor
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck CancerPhase 2Ann Arbor
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)Phase 2Ann Arbor
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaPhase 3Ann Arbor
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialPhase 2Ann Arbor
Living Well With LymphomaN/AAnn Arbor
Localized Leiomyosarcoma Biomarker Protocol—Ann Arbor
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaPhase 2Ann Arbor
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies—Ann Arbor
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsPhase 2/3Ann Arbor
Longitudinal Oral Microbiome Sampling for BE—Ann Arbor
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionPhase 2Ann Arbor
Lurbinectedin in FET-Fused TumorsPhase 1/2Ann Arbor
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Phase 2Ann Arbor
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasPhase 3Ann Arbor
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous MelanomaN/AAnn Arbor
Metastatic Leiomyosarcoma Biomarker Protocol—Ann Arbor
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of RecurrencePhase 3Ann Arbor
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed MedulloblastomaPhase 2Ann Arbor
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer—Ann Arbor
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialPhase 2Ann Arbor
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyPhase 2Ann Arbor
National Liver Cancer Screening TrialPhase 4Ann Arbor
Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer SyndromesN/AAnn Arbor
Neoadjuvant Darovasertib in Primary Uveal MelanomaPhase 3Ann Arbor
Neuroblastoma Biology Study—Ann Arbor
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)Phase 3Ann Arbor
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS TumorsPhase 1Ann Arbor
Obeticholic Acid for Prevention in Barrett's EsophagusPhase 2Ann Arbor
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaPhase 2Ann Arbor
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsPhase 2Ann Arbor
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPhase 3Ann Arbor
Pan Tumor Rollover StudyPhase 2Ann Arbor
Pancreatic Cancer Early Detection Consortium—Ann Arbor
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasPhase 2Ann Arbor
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Ann Arbor
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT TrialPhase 2Ann Arbor
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With CancerPhase 4Ann Arbor
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasPhase 1Ann Arbor
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaPhase 1Ann Arbor
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaPhase 1/2Ann Arbor
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaPhase 2Ann Arbor
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 3Ann Arbor
Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisPhase 3Ann Arbor
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)Phase 3Ann Arbor
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaPhase 3Ann Arbor
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaPhase 1Ann Arbor
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])Phase 2Ann Arbor
Precision-Based Genomics in Prostate Cancer—Ann Arbor
Prediction Augmented Screening InitiativeN/AAnn Arbor
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell TransplantationN/AAnn Arbor
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRIN/AAnn Arbor
Project: Every Child for Younger Patients With Cancer—Ann Arbor
Prostate Active Surveillance Study—Ann Arbor
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the TongueN/AAnn Arbor
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)Phase 3Ann Arbor
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2Ann Arbor
Randomized Phase II Trial of Targeted Radiation With no Castration for McrpcPhase 2Ann Arbor
Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation—Ann Arbor
Repositioning Immunotherapy in VetArans With Lung CancerPhase 2Ann Arbor
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCPhase 2Ann Arbor
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerPhase 2Ann Arbor
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerPhase 1/2Ann Arbor
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3Ann Arbor
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal CancerPhase 3Ann Arbor
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy—Ann Arbor
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaPhase 3Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Ann Arbor
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3Ann Arbor
Safety and Durability of Sirolimus for Treatment of LAM—Ann Arbor
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid TumorsPhase 1Ann Arbor
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid TumorsPhase 1/2Ann Arbor
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Ann Arbor
Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer SurvivorsN/AAnn Arbor
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPhase 3Ann Arbor
Spine Oncology Registry—Ann Arbor
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 3Ann Arbor
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain MetastasesPhase 3Ann Arbor
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPhase 3Ann Arbor
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentPhase 2Ann Arbor
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsPhase 1Ann Arbor
Study of ACR-2316 in Specific Advanced Solid TumorsPhase 1/2Ann Arbor
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerPhase 1/2Ann Arbor
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver MetastasesPhase 2Ann Arbor
Study of DCC-2812 in Participants With Advanced Genitourinary CancersPhase 1Ann Arbor
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaPhase 1/2Ann Arbor
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3Ann Arbor
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerPhase 2Ann Arbor
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaPhase 2Ann Arbor
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerPhase 3Ann Arbor
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic CarcinomaPhase 1/2Ann Arbor
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantPhase 2Ann Arbor
Study of SGR-3515 In Participants With Advanced Solid Tumors.Phase 1Ann Arbor
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerPhase 2Ann Arbor
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIPhase 2Ann Arbor
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerPhase 3Ann Arbor
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)Phase 3Ann Arbor
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)Phase 1Ann Arbor
Suprachoroidal Administration in Subjects With Metastases to the ChoroidPhase 2Ann Arbor
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPhase 3Ann Arbor
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study—Ann Arbor
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade DysplasiaN/AAnn Arbor
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPhase 2Ann Arbor
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesPhase 1Ann Arbor
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) EpendymomaPhase 2Ann Arbor
Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer—Ann Arbor
Targeted Pediatric High-Grade Glioma Therapy—Ann Arbor
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPhase 2Ann Arbor
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Ann Arbor
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Ann Arbor
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPhase 1/2Ann Arbor
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerPhase 3Ann Arbor
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaPhase 3Ann Arbor
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialPhase 3Ann Arbor
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerPhase 3Ann Arbor
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize TrialPhase 3Ann Arbor
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaPhase 1Ann Arbor
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Phase 2Ann Arbor
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialPhase 3Ann Arbor
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER StudyPhase 3Ann Arbor
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerPhase 3Ann Arbor
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaPhase 2Ann Arbor
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyPhase 3Ann Arbor
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary BlastomaPhase 3Ann Arbor
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201Phase 1Ann Arbor
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Phase 3Ann Arbor
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentPhase 3Ann Arbor
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerPhase 2Ann Arbor
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3Ann Arbor
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerPhase 2/3Ann Arbor
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal CavityPhase 2/3Ann Arbor
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialPhase 2Ann Arbor
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur TrialPhase 2Ann Arbor
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerPhase 2Ann Arbor
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerPhase 3Ann Arbor
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaPhase 2Ann Arbor
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialPhase 2Ann Arbor
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaPhase 2Ann Arbor
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsPhase 2Ann Arbor
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPhase 2/3Ann Arbor
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersPhase 2Ann Arbor
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2Ann Arbor
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)Phase 2Ann Arbor
The Cancer of the Pancreas Screening-5 CAPS5)StudyPhase 3Ann Arbor
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPhase 1/2Ann Arbor
The SEQUENCE TrialN/AAnn Arbor
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Ann Arbor
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerPhase 3Ann Arbor
Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsPhase 2Ann Arbor
Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer SurvivorsN/AAnn Arbor
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorPhase 2Ann Arbor
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemPhase 2Ann Arbor
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)Phase 3Ann Arbor
Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)N/AAnn Arbor
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With CancerPhase 3Ann Arbor
UBX-303061 in Subjects With Relapsed/Refractory B-Cell MalignanciesPhase 1Ann Arbor
University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2—Ann Arbor
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE TrialN/AAnn Arbor
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)Phase 3Ann Arbor
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaPhase 1/2Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyN/AAnn Arbor
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain TumorsPhase 1Ann Arbor
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid LeukemiaPhase 3Ann Arbor
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerPhase 2Ann Arbor
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryPhase 2Ann Arbor
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto—Ann Arbor
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Phase 3Battle Creek
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3Battle Creek
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage MelanomaPhase 3Battle Creek
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)N/ABattle Creek
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsPhase 3Battle Creek
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPhase 2Battle Creek
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaPhase 2Battle Creek
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerPhase 3Battle Creek
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialPhase 3Battle Creek
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast CancerN/ABay City
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPhase 3Bay City
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal CancerPhase 2Bay City
Ask Questions About Clinical TrialsN/ABay City
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid MalignanciesPhase 1Bay City
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerPhase 2Bay City
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Phase 2Big Rapids
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Phase 1/2Big Rapids
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Phase 3Big Rapids
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerPhase 3Big Rapids
Shield Post-Approval Study Protocol—Bloomfield Township
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerPhase 3Brighton
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerPhase 3Brighton
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Brighton
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)Phase 2Brighton
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Phase 2Brighton
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)Phase 2Brighton
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialPhase 2Brighton
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3Brighton
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLPhase 3Brighton
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialPhase 3Brighton
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPhase 2Brighton
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2Brighton
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPhase 2Brighton
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)Phase 2Brighton
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal CancerPhase 3Brownstown
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialPhase 3Brownstown
The Vanguard Study: Testing a New Way to Screen for CancerN/ABrownstown
A Study of the TheraBionic P1 Device in Breast CancerN/AClarkston
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic CancerPhase 2Clarkston
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)Phase 3Clarkston
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral NeuropathyPhase 3Clinton Township
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPhase 1/2Dearborn
A Study of IBI363 in Subjects with Advanced Solid MalignanciesPhase 2Dearborn
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionPhase 3Dearborn
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerPhase 2Dearborn
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsPhase 3Dearborn
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerPhase 3Dearborn
Study of Aritinercept in Patients With Generalized Myasthenia GravisPhase 1/2Dearborn
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)—Detriot
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerPhase 1/2Detroit
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsPhase 1/2Detroit
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)Phase 1/2Detroit
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9Phase 1/2Detroit
A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.N/ADetroit
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesPhase 1/2Detroit
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain MetastasesPhase 1Detroit
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian CancerPhase 1Detroit
A First-in-Human Study of YL217 in Patients With Advanced Solid TumorsPhase 1Detroit
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsPhase 1/2Detroit
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Phase 3Detroit
A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelPhase 4Detroit
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa—Detroit
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsPhase 1Detroit
A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.Phase 1Detroit
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.Phase 1/2Detroit
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid TumorsPhase 1/2Detroit
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway MutationsPhase 1/2Detroit
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsPhase 1/2Detroit
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.Phase 1/2Detroit
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPCPhase 1/2Detroit
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerPhase 2Detroit
A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaPhase 2Detroit
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 2Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)Phase 3Detroit
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).Phase 3Detroit
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerPhase 3Detroit
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationPhase 2Detroit
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)Phase 1/2Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsPhase 1/2Detroit
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsPhase 1/2Detroit
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Phase 3Detroit
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain DiseasePhase 2Detroit
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPhase 3Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsPhase 1/2Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 3Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyPhase 3Detroit
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)Phase 1Detroit
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaPhase 1Detroit
A Study of 177Lu-FAP-2286 in Advanced Solid TumorsPhase 1/2Detroit
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.Phase 1Detroit
A Study of ASP1002 in Adults for Treatment of Solid TumorsPhase 1Detroit
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/2Detroit
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)Phase 3Detroit
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerPhase 2Detroit
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerPhase 3Detroit
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerPhase 2Detroit
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsPhase 1/2Detroit
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPhase 1/2Detroit
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)Phase 3Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsPhase 1Detroit
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C MutationPhase 1/2Detroit
A Study of DB-1310 in Advanced/Metastatic Solid TumorsPhase 1/2Detroit
A Study of DM005 in Patients With Advanced Solid TumorsPhase 1/2Detroit
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.N/ADetroit
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered MalignanciesPhase 1/2Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsPhase 1/2Detroit
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)Phase 1Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesPhase 1/2Detroit
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaPhase 3Detroit
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell CarcinomaPhase 1Detroit
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)Phase 1/2Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesPhase 1Detroit
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPhase 3Detroit
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)Phase 3Detroit
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Phase 2/3Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)Phase 1Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid TumorsPhase 1Detroit
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.Phase 2Detroit
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.Phase 1Detroit
A Study of Methylprednisolone in People Having Liver SurgeryPhase 3Detroit
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)Phase 1Detroit
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)Phase 2Detroit
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)Phase 2Detroit
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)Phase 1/2Detroit
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic CancerPhase 2/3Detroit
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Phase 3Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1Detroit
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 3Detroit
A Study of TAK-188 in Adults With Advanced or Spreading Solid TumorsPhase 1/2Detroit
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung CancerPhase 1Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractPhase 3Detroit
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)Phase 3Detroit
A Study of ZL-1310 in Participants With Selected Solid TumorsPhase 1/2Detroit
A Study of ZL-1310 in Subjects With Small Cell Lung CancerPhase 1Detroit
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)Phase 1/2Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsPhase 1/2Detroit
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsPhase 3Detroit
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab SoravtansinePhase 2Detroit
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerPhase 2Detroit
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)Phase 2Detroit
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerPhase 2Detroit
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerPhase 1/2Detroit
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaPhase 3Detroit
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)Phase 3Detroit
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaPhase 3Detroit
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsPhase 3Detroit
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)Phase 3Detroit
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerPhase 3Detroit
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 3Detroit
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerPhase 2Detroit
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)Phase 3Detroit
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPhase 3Detroit
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Phase 1/2Detroit
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesPhase 1/2Detroit
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)Phase 1Detroit
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsPhase 1Detroit
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabPhase 1/2Detroit
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderPhase 2Detroit
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1Detroit
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsPhase 1/2Detroit
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Phase 2Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPhase 2Detroit
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerPhase 3Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPhase 3Detroit
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPhase 2/3Detroit
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsPhase 1/2Detroit
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)Phase 1/2Detroit
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaPhase 3Detroit
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received TreatmentPhase 1/2Detroit
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis—Detroit
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodPhase 2Detroit
ASV Therapy for InsomniaN/ADetroit
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)Phase 3Detroit
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic CancerPhase 2Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer SurvivorsN/ADetroit
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.Phase 1Detroit
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsPhase 1Detroit
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Phase 4Detroit
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerPhase 2Detroit
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell TransplantPhase 2Detroit
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsPhase 1Detroit
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePhase 3Detroit
BP1001-A in Patients With Advanced or Recurrent Solid TumorsPhase 1Detroit
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsPhase 2Detroit
Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCTN/ADetroit
C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)N/ADetroit
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsPhase 1/2Detroit
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisPhase 3Detroit
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialPhase 2Detroit
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense BreastsN/ADetroit
Connect for Cancer Prevention Study (Connect)—Detroit
Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer SurvivorsN/ADetroit
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid TumorsPhase 1Detroit
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment—Detroit
Efficacy and Safety of the CG-100 Intraluminal Bypass DeviceN/ADetroit
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal CancerPhase 1/2Detroit
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaPhase 1Detroit
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Phase 3Detroit
FOCUS ON US: Adapting the FOCUS Program for Sexual and Gender Minority (SGM) Cancer Patients and CaregiversN/ADetroit
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerPhase 2Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3Phase 1Detroit
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid TumorsPhase 1Detroit
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)Phase 1/2Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerPhase 1/2Detroit
First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsPhase 1/2Detroit
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsPhase 1/2Detroit
First-in-human Study of Interferon-y PET Imaging to Assess Response to ImmunotherapyPhase 1Detroit
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerPhase 1/2Detroit
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and BortezomibPhase 2Detroit
HPC Offered for PRESERVE Expansion—Detroit
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple MyelomaPhase 2Detroit
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial CancerPhase 3Detroit
Increasing Knowledge and Interest in Cancer Clinical TrialsN/ADetroit
Intraoral Hypothermia Device for Preserving Taste During RadiationEarly 1Detroit
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerPhase 2Detroit
JAB-2485 Activity in Adult Patients With Advanced Solid TumorsPhase 1/2Detroit
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3Detroit
KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPhase 1Detroit
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-NaïvePhase 1/2Detroit
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine MetastasesN/ADetroit
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer—Detroit
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Phase 3Detroit
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerPhase 2Detroit
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTPhase 3Detroit
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCPhase 3Detroit
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerPhase 2Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsPhase 1Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerPhase 1/2Detroit
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerPhase 1Detroit
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)Phase 2/3Detroit
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)Phase 1Detroit
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)Phase 2Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.Phase 1Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsPhase 1Detroit
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung CancerPhase 1Detroit
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsPhase 1Detroit
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerPhase 1/2Detroit
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After ImmunotherapyPhase 2/3Detroit
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaPhase 3Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)Phase 3Detroit
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerPhase 3Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsPhase 1/2Detroit
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsPhase 3Detroit
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3Detroit
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3Detroit
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerPhase 3Detroit
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCPhase 1Detroit
Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALAPhase 2Detroit
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALAPhase 2Detroit
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationPhase 2Detroit
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerPhase 3Detroit
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT—Detroit
Radioembolization Versus External Radiation TherapyPhase 2Detroit
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)—Detroit
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)—Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2Detroit
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid TumorsPhase 1/2Detroit
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Phase 3Detroit
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyPhase 1Detroit
Sacral Neuromodulation for Male Overactive Bladder (MOAB)N/ADetroit
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing ChemotherapyPhase 2Detroit
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell LymphomaPhase 2Detroit
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsPhase 1Detroit
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsPhase 1/2Detroit
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1Detroit
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid TumorsPhase 1/2Detroit
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Phase 3Detroit
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerN/ADetroit
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsPhase 1/2Detroit
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPhase 3Detroit
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsPhase 1/2Detroit
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTPhase 3Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerPhase 1/2Detroit
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLPhase 2Detroit
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesPhase 1Detroit
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 3Detroit
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsPhase 1/2Detroit
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementPhase 2Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Phase 1/2Detroit
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPhase 2/3Detroit
Study of ORIC-944 in Patients With Metastatic Prostate CancerPhase 1Detroit
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPhase 3Detroit
Study of Olverembatinib (HQP1351) in Patients With CML-CPPhase 3Detroit
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Phase 3Detroit
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationPhase 1Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid TumorsPhase 1Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/2Detroit
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene AbnormalitiesPhase 1/2Detroit
Study of SGN1 in Patients With Advanced Solid TumorPhase 1/2Detroit
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPhase 2Detroit
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3Detroit
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationPhase 3Detroit
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPhase 1Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsPhase 1/2Detroit
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)Phase 2Detroit
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple MyelomaPhase 1Detroit
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPhase 3Detroit
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsPhase 1/2Detroit
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsPhase 3Detroit
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 3Detroit
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETPhase 3Detroit
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic ImpairmentPhase 1Detroit
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.Phase 3Detroit
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsPhase 1/2Detroit
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerPhase 1Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Detroit
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyPhase 3Detroit
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1Detroit
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Phase 1/2Detroit
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET DysregulationPhase 2Detroit
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Phase 1/2Detroit
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsPhase 2/3Detroit
Engaging College Students in Developing and Testing a Video-based Intervention for HPV Vaccination PromotionN/AEast Lansing
Support for Bereaved Cancer CaregiversN/AEast Lansing
Reaching Rural Cancer Survivors Who Smoke Using Text-Based ProgramPhase 3Escanaba
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaPhase 2Escanaba
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsPhase 1Farmington Hills
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsPhase 1/2Farmington Hills
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 3Farmington Hills
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)Phase 3Farmington Hills
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)Phase 2Farmington Hills
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Phase 3Farmington Hills
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Phase 3Farmington Hills
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast CancerPhase 2Flint
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical ProstatectomyN/AFlint
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the PancreasPhase 2Flint
Registry Study for Radiation Therapy Outcomes—Flint
The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care—Flint
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsPhase 1/2Grand Rapids
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract CancerPhase 1/2Grand Rapids
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)Phase 1/2Grand Rapids
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Phase 3Grand Rapids
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)Phase 2Grand Rapids
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerPhase 1/2Grand Rapids
A Clinical Trial to Assess COM503 in Participants With Advanced Solid MalignanciesPhase 1Grand Rapids
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyPhase 1/2Grand Rapids
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPhase 1Grand Rapids
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid TumorsPhase 1Grand Rapids
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCPhase 3Grand Rapids
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyPhase 2Grand Rapids
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Phase 1/2Grand Rapids
A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study—Grand Rapids
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPhase 1Grand Rapids
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesPhase 1Grand Rapids
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerPhase 2Grand Rapids
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasPhase 1Grand Rapids
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)Phase 2Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsPhase 1Grand Rapids
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product—Grand Rapids
A Study in Patients With Metastatic Castration-Resistant Prostate CancerPhase 1Grand Rapids
A Study of ADRX-0405 in Subjects With Select Advanced Solid TumorsPhase 1Grand Rapids
A Study of APG-3288 in Relapsed/Refractory Blood CancersPhase 1Grand Rapids
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AMLPhase 1Grand Rapids
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid TumorsPhase 1Grand Rapids
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)Phase 1Grand Rapids
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsPhase 1/2Grand Rapids
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)Phase 1Grand Rapids
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3Grand Rapids
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerPhase 1/2Grand Rapids
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)Phase 1/2Grand Rapids
A Study of JNJ-87890387 for Advanced Solid TumorsPhase 1Grand Rapids
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric CancersPhase 1Grand Rapids
A Study of JNJ-95804306 for Relapsed or Refractory Hematological MalignanciesPhase 1Grand Rapids
A Study of JNJ-98768111 in Participants With Advanced Prostate CancerPhase 1Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsPhase 1Grand Rapids
A Study of Lorigerlimab in Participants With Advanced Solid TumorsPhase 2Grand Rapids
A Study of MGC026 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
A Study of MGC028 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
A Study of MT-4561 in Patients With Various Advanced Solid TumorsPhase 1/2Grand Rapids
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Phase 3Grand Rapids
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid TumorsPhase 1/2Grand Rapids
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.Phase 1Grand Rapids
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid TumorsPhase 1/2Grand Rapids
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid TumorsPhase 1Grand Rapids
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerPhase 1Grand Rapids
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Phase 1/2Grand Rapids
A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsPhase 1Grand Rapids
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 3Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsPhase 1Grand Rapids
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsPhase 3Grand Rapids
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)Phase 1Grand Rapids
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
A Study of YL242 in Subjects With Advanced Solid TumorsPhase 1/2Grand Rapids
A Study of ZW251 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Phase 2/3Grand Rapids
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With CancerPhase 1Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPhase 1Grand Rapids
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerPhase 1Grand Rapids
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1Grand Rapids
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsPhase 1Grand Rapids
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab AdizutecanPhase 2Grand Rapids
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsPhase 1Grand Rapids
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsPhase 1Grand Rapids
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursPhase 1/2Grand Rapids
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor TherapiesPhase 1/2Grand Rapids
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Phase 1/2Grand Rapids
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPhase 3Grand Rapids
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)Phase 1Grand Rapids
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid TumorsPhase 1Grand Rapids
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid TumorsPhase 1Grand Rapids
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsPhase 1Grand Rapids
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)Phase 3Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsPhase 1/2Grand Rapids
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsPhase 1/2Grand Rapids
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesPhase 1Grand Rapids
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid MalignanciesPhase 1Grand Rapids
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal CancerPhase 1Grand Rapids
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsPhase 1Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.Phase 1Grand Rapids
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate CancerPhase 1/2Grand Rapids
ARC101 in Advanced Solid TumorsPhase 1Grand Rapids
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsPhase 1Grand Rapids
An Early Phase Trial of RPTR-1-201 in Advanced Solid TumorsPhase 1/2Grand Rapids
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.Phase 3Grand Rapids
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsPhase 2Grand Rapids
CT-95 in Advanced Cancers Associated With Mesothelin ExpressionPhase 1Grand Rapids
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaEarly 1Grand Rapids
DBC-664 in Adult Patients With Solid TumorsPhase 1Grand Rapids
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])Phase 2/3Grand Rapids
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLPhase 2Grand Rapids
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)Phase 1/2Grand Rapids
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPhase 3Grand Rapids
First-Time-in-Human Study of GSK5471713 in Adults With mCRPCPhase 1/2Grand Rapids
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor MalignanciesPhase 1/2Grand Rapids
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid TumorsPhase 1/2Grand Rapids
Groningen International Study on Sentinel Nodes in Vulvar Cancer-IIIPhase 2Grand Rapids
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)Phase 3Grand Rapids
JUR-003 in Adult Patients With Metastatic Prostate CancerPhase 1Grand Rapids
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia—Grand Rapids
Measuring Surgical Recovery After Radical Cystectomy—Grand Rapids
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesPhase 1Grand Rapids
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPhase 2Grand Rapids
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—Grand Rapids
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell CarcinomaPhase 1Grand Rapids
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy—Grand Rapids
Pan-tumor MRD Study—Grand Rapids
Pediatric Precision Laboratory Advanced Neuroblastoma TherapyPhase 2Grand Rapids
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionPhase 1Grand Rapids
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerPhase 1Grand Rapids
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsPhase 1/2Grand Rapids
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesPhase 1/2Grand Rapids
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)Phase 3Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersPhase 1Grand Rapids
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyPhase 3Grand Rapids
Quality of End-of-Life Care for Children With Cancer—Grand Rapids
REC-7735 in Participants With Solid TumorsPhase 1/2Grand Rapids
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaPhase 2Grand Rapids
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected SarcomasPhase 1/2Grand Rapids
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsPhase 1/2Grand Rapids
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Phase 3Grand Rapids
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsPhase 1Grand Rapids
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)Phase 1/2Grand Rapids
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerPhase 1/2Grand Rapids
Study of AUBE00 in Patients With Solid TumorsPhase 1Grand Rapids
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaPhase 3Grand Rapids
Study of CP-383 in Patients With Advanced or Metastatic Solid TumorsPhase 1/2Grand Rapids
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)Phase 2Grand Rapids
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaPhase 2/3Grand Rapids
Study of GS-2426 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerPhase 1/2Grand Rapids
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPhase 1/2Grand Rapids
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid TumorsPhase 1Grand Rapids
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaPhase 1/2Grand Rapids
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsPhase 1Grand Rapids
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaPhase 1/2Grand Rapids
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400Phase 1Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPhase 1Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPhase 1/2Grand Rapids
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerPhase 3Grand Rapids
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) CancersPhase 2Grand Rapids
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)Phase 2/3Grand Rapids
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsPhase 1/2Grand Rapids
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Phase 1/2Grand Rapids
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Phase 1/2Grand Rapids
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Phase 1/2Grand Rapids
TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasPhase 1Grand Rapids
TLN-372 in Advanced KRAS Mutant Solid TumorsPhase 1Grand Rapids
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & LymphomaPhase 1Grand Rapids
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALLPhase 2Grand Rapids
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.Phase 3Grand Rapids
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid TumorsPhase 1Grand Rapids
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid TumorsPhase 1Grand Rapids
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesPhase 1/2Grand Rapids
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles—Grosse Pointe Woods
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationPhase 3Grosse Pointe Woods
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)Phase 3Holland
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome—Kalamazoo
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPhase 3Lansing
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)Phase 2Lansing
Empowering Vietnamese AmericansN/ALansing
Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine ProceduresPhase 4Lansing
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPhase 2Lansing
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)—Lansing
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell CarcinomaPhase 3Midland
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaPhase 2North Shores
Study of Oral MRT-2359 With Apalutamide in Prostate CancerPhase 2Novi
The Ailliance Post-Market Clinical StudyN/ARochester Hills
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3Royal Oak
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerPhase 3Royal Oak
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningN/ARoyal Oak
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerPhase 1Royal Oak
Active Surveillance SNEP Assay Registry Trial for Prostate Cancer—Royal Oak
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)Phase 3Royal Oak
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerPhase 4Royal Oak
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCPhase 2Royal Oak
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsPhase 1Royal Oak
Quantitative MRI Assessment of Breast Cancer Therapy Response—Royal Oak
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer—Royal Oak
The PREDICT Registry:—Royal Oak
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerPhase 3Saginaw
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer—Saginaw
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)Phase 3Sterling Heights
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerPhase 3Sterling Heights
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)Phase 3Sterling Heights
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3Sterling Heights
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Phase 3Traverse City
Empathic Communication Skills (ECS) TrainingN/ATraverse City
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBCPhase 1Troy
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder CancerPhase 1/2Troy
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerPhase 2Troy
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States—Troy
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TPhase 2Troy
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGPhase 1/2Troy
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.Phase 3Troy
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Phase 2Troy
A Study of ASP3082 in Adults With Advanced Solid TumorsPhase 1Ypsilanti
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 3Ypsilanti
CtDNA Based MRD Testing for NAC Monitoring in TNBC—Ypsilanti
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerPhase 1/2Ypsilanti
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Phase 3Ypsilanti
Prospective Study to Assess a Diagnostic Aid for Cancer—Ypsilanti

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.